Literature DB >> 26487956

Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.

Jane E Rogers1, Ninoska N Silva1, Cathy Eng1.   

Abstract

Metastatic squamous cell carcinoma (SCC) of the anal canal is rare with limited data regarding treatment. Epidermal growth factor receptor (EGFR) expression has been observed in SCC of the anal canal and Kristen rat sarcoma vial oncogene (KRAS) mutations are rare. EGFR monoclonal antibodies, cetuximab and panitumumab, represent a potential option in this patient population. We report a metastatic SCC of the anal canal patient treated with cetuximab in combination with cisplatin plus 5-Fluorouracil (5-FU) that had a dramatic response.

Entities:  

Keywords:  Cetuximab; anal cancer; epidermal growth factor receptor (EGFR) inhibitors

Year:  2015        PMID： 26487956      PMCID： PMC4570906          DOI： 10.3978/j.issn.2078-6891.2015.035

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  12 in total

1.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

2.  Cetuximab in refractory squamous cell carcinoma of the anal canal.

Authors:  Jane E Rogers; Cathy Eng
Journal:  J Gastrointest Cancer       Date:  2014-12

3.  Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.

Authors:  Nadine Lukan; Philipp Ströbel; Andreas Willer; Melanie Kripp; Dietmar Dinter; Sabine Mai; Andreas Hochhaus; Ralf-Dieter Hofheinz
Journal:  Oncology       Date:  2009-11-17       Impact factor: 2.935

4.  KRAS and BRAF mutations in anal carcinoma.

Authors:  Eva Serup-Hansen; Dorte Linnemann; Estrid Høgdall; Poul Flemming Geertsen; Hanne Havsteen
Journal:  APMIS       Date:  2014-09-22       Impact factor: 3.205

5.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

6.  K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?

Authors:  Maria Giulia Zampino; Elena Magni; Angelica Sonzogni; Giuseppe Renne
Journal:  Cancer Chemother Pharmacol       Date:  2009-09-02       Impact factor: 3.333

7.  The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.

Authors:  Muhammad W Saif; Ewa Kontny; Kostas N Syrigos; Armin Shahrokni
Journal:  J Oncol       Date:  2011-06-13       Impact factor: 4.375

8.  The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Authors:  Cathy Eng; George J Chang; Y Nancy You; Prajnan Das; Miguel Rodriguez-Bigas; Yan Xing; Jean-Nicolas Vauthey; Jane E Rogers; Aki Ohinata; Priyanka Pathak; Salil Sethi; Jonathan K Phillips; Christopher H Crane; Robert A Wolff
Journal:  Oncotarget       Date:  2014-11-30

9.  EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

Authors:  A Paliga; R Onerheim; A Gologan; G Chong; A Spatz; T Niazi; A Garant; D Macheto; T Alcindor; T Vuong
Journal:  Br J Cancer       Date:  2012-10-23       Impact factor: 7.640

10.  KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

Authors:  Andrea Casadei Gardini; Laura Capelli; Paola Ulivi; Massimo Giannini; Eva Freier; Stefano Tamberi; Emanuela Scarpi; Alassandro Passardi; Wainer Zoli; Angela Ragazzini; Dino Amadori; Giovanni Luca Frassineti
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240
View more
  2 in total

Review 1.  Systemic Therapies for Advanced Squamous Cell Anal Cancer.

Authors:  Francesco Sclafani; Sheela Rao
Journal:  Curr Oncol Rep       Date:  2018-05-04       Impact factor: 5.075

2.  No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

Authors:  Laura Capelli; Andrea Casadei Gardini; Emanuela Scarpi; Giovanni Luca Frassineti; Luca Saragoni; Maurizio Puccetti; Mario Scartozzi; Massimo Giannini; Stefano Tamberi; Jody Corbelli; Paola Ulivi
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.